Predictive Technology Group (Predictive Technology Group) ROCE % : -71.65% (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Predictive Technology Group's annualized ROCE % for the quarter that ended in Mar. 2021 was -71.65%.

Predictive Technology Group ROCE % Historical Data

The historical data trend for Predictive Technology Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group ROCE % Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

ROCE %

Get a 7-Day Free Trial

-11.99

-11.74

-17.74

-18.32

-99.70

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
ROCE %	Get a 7-Day Free Trial															-46.94	-197.20	-52.89	-59.24	-71.65

Predictive Technology Group ROCE % Calculation

Predictive Technology Group's annualized ROCE % for the fiscal year that ended in Jun. 2020 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2020 )		(A: Jun. 2019 )		(A: Jun. 2020 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2020 )		(A: Jun. 2019 )		(A: Jun. 2020 )
	=	-95.962	/	( ( (143.578 - 14.075)	+	(83.842 - 20.836) )	/ 2 )
	=	-95.962	/	( (129.503	+	63.006)	/ 2 )
	=	-95.962	/	96.2545
	=	-99.70 %

Predictive Technology Group's ROCE % of for the quarter that ended in Mar. 2021 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2021 )		(Q: Dec. 2020 )		(Q: Mar. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2021 )		(Q: Dec. 2020 )		(Q: Mar. 2021 )
	=	-27.72	/	( ( (70.452 - 29.41)	+	(66.959 - 30.629) )	/ 2 )
	=	-27.72	/	( ( 41.042	+	36.33 )	/ 2 )
	=	-27.72	/	38.686
	=	-71.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2021) EBIT data.

Predictive Technology Group (OTCPK:PRED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Predictive Technology Group ROCE % Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.